In ongoing litigation over Celltrion and Pfizer’s infliximab biosimilar, Inflectra, a Massachusetts district court has granted Celltrion’s motion for leave to file a motion for summary judgment of non-infringement.
In ongoing litigation over Celltrion and Pfizer’s infliximab biosimilar, Inflectra, a Massachusetts district court has granted Celltrion’s motion for leave to file a motion for summary judgment of non-infringement.
Janssen, maker of the reference infliximab, Remicade, has claimed that the biosimilar developer infringed on a patent, which covers chemically defined media compositions for the culture of eukaryotic cells, in producing Inflectra.
In support of its motion, Celltrion said that Janssen’s patent is not new and that the court should terminate the case based on ensnarement, or the principle that prior art (elements of patented information that are already publicly available) restricts the scope of what the alleging party can assert under the doctrine of equivalents (a legal rule holding that, while a product may not literally infringe on a patented invention, the product may have elements that are equivalent to those described in a patent).
According to Celltrion, if Janssen wants to claim that Celltrion infringed on Janssen’s patent through the doctrine of equivalents, Janssen should have the burden of proving that the scope of equivalency does not encompass any prior art related to the patent.
“There is every reason for the Court to consider ensnarement on a motion for summary judgment” in this case, according to the motion, especially given the fact that GlaxoSmithKline has already disclosed the same ingredients, at concentrations that overlap heavily with Janssen’s patented ingredients and concentrations, elsewhere. These overlapping ranges establish a case for the obviousness of Janssen’s invention, says Celltrion.
The motion proposes a deadline of May 10, 2018, for Janssen to file its opposition, after which Celltrion would file its reply brief by May 28, 2018.
In October of 2017, the court denied Celltrion’s motion to dismiss this case for lack of standing.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.